CARVEDILOL PHOSPHATE
Clinical safety rating: caution
Other drugs that lower heart rate or blood pressure can have additive effects Abrupt withdrawal may exacerbate angina pectoris or cause myocardial infarction.
Competitive beta-blocker with alpha1-blocking activity; decreases cardiac output, reduces peripheral vascular resistance.
| Metabolism | Extensively metabolized by CYP2D6 and CYP2C9 with some contribution from CYP3A4 and CYP1A2; undergoes glucuronidation. |
| Excretion | Primarily hepatic metabolism (CYP2D6 and CYP2C9) followed by biliary excretion into feces; ~60% fecal elimination as metabolites, ~16% renal elimination of unchanged drug plus metabolites. |
| Half-life | 7-10 hours (terminal elimination half-life); clinical context: supports twice-daily dosing for sustained beta-blockade. |
| Protein binding | 98-99% bound; primarily to albumin. |
| Volume of Distribution | ~1.5 L/kg; indicates extensive extravascular distribution. |
| Bioavailability | Oral: 25-35% due to extensive first-pass metabolism; increases with hepatic impairment. |
| Onset of Action | Oral: 30-60 minutes for decrease in heart rate; antihypertensive effect begins within 1-2 hours. |
| Duration of Action | 12-24 hours; clinical notes: beta-blocking effect persists for at least 12 hours, supporting twice-daily dosing. |
6.25 mg orally twice daily, titrated up to a maximum of 25 mg twice daily for heart failure; 12.5 mg orally once daily for hypertension, titrated to 25-50 mg daily.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (CrCl <20 mL/min), use cautiously with a starting dose of 6.25 mg twice daily and titrate slowly. |
| Liver impairment | Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, use with caution; no specific dose adjustment guidelines are established, but initiate at lowest dose (3.125 mg twice daily). |
| Pediatric use | For heart failure: starting dose 0.1 mg/kg/dose orally twice daily (maximum 1.6 mg/kg/day, up to 25 mg twice daily). For hypertension: 0.1 mg/kg/dose twice daily, adjusted to effect. |
| Geriatric use | Start at 3.125 mg twice daily for heart failure; titrate slowly due to increased sensitivity. For hypertension, initiate at 12.5 mg once daily; monitor renal function and blood pressure closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other drugs that lower heart rate or blood pressure can have additive effects Abrupt withdrawal may exacerbate angina pectoris or cause myocardial infarction.
| FDA category | Animal |
| Breastfeeding | Minimal excretion into breast milk (M/P ratio approximately 0.8). AAP considers compatible with breastfeeding; monitor infant for bradycardia and hypotension. |
| Teratogenic Risk | First trimester: Crosses placenta; limited human data; animal studies show increased fetal resorptions, delayed development at maternotoxic doses. Second/third trimester: Risk of fetal bradycardia, intrauterine growth restriction (IUGR), and neonatal hypotension/hypoglycemia. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | heart failure |
| Serious Effects |
["Decompensated heart failure requiring IV inotropes","Severe bradycardia, sick sinus syndrome (without pacemaker), or advanced heart block","Cardiogenic shock","Severe hepatic impairment","Bronchial asthma or bronchospastic conditions","Hypersensitivity to carvedilol or any component"]
| Precautions | ["May worsen heart failure or cause fluid retention","Bradycardia, hypotension, and syncope","Abrupt withdrawal may exacerbate angina or myocardial infarction","Mask symptoms of hypoglycemia in diabetics","Peripheral vascular disease exacerbation","Bronchospasm in patients with COPD or asthma","May mask signs of hyperthyroidism"] |
| Food/Dietary | Take with food to decrease the risk of orthostatic hypotension. Avoid excessive alcohol, which can enhance hypotensive effects. No specific food restrictions. |
Loading safety data…
| Fetal Monitoring | Maternal: Heart rate, blood pressure, signs of heart failure. Fetal: Heart rate and growth via ultrasound. Neonatal: Observe for bradycardia, hypoglycemia, and hypotension for 24-48 hours post-delivery. |
| Fertility Effects | No known significant effects on fertility. Rarely, impotence or decreased libido may occur in males, but reversible upon discontinuation. |
| Clinical Pearls | Carvedilol phosphate is a nonselective beta-blocker with alpha1-blocking activity used in heart failure (NYHA II-III), hypertension, and left ventricular dysfunction post-MI. It reduces mortality in heart failure but requires slow titration to avoid hypotension. Monitor for bradycardia, dizziness, and fluid retention. Use with caution in asthma, COPD, and peripheral vascular disease. Avoid abrupt discontinuation. It may mask hypoglycemia in diabetics. Dosing should be taken with food to minimize orthostatic hypotension. |
| Patient Advice | Take with food to reduce dizziness and lightheadedness. · Do not stop suddenly; taper as directed to avoid worsening of chest pain or heart attack. · Avoid alcohol, which can lower blood pressure further. · Weigh yourself daily and report weight gain or swelling to your doctor. · Watch for slow heart rate, fainting, or shortness of breath. · If you have diabetes, monitor blood sugar carefully as signs of low sugar may be masked. · Avoid driving or operating machinery until you know how this drug affects you. |